 | Minerva Neurosciences Inc (NERV) Expected to Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - May 17 at 8:48 AM |
| Minerva Neurosciences Inc (NERV) Major Shareholder Venture Associates L. Index III Sells 36,574 Shares
www.americanbankingnews.com - May 16 at 8:38 PM |
| Venture Associates L. Index III Sells 134,828 Shares of Minerva Neurosciences Inc (NERV) Stock
www.americanbankingnews.com - May 16 at 8:18 PM |
 | Minerva Stock Drops On Initial Reaction To Data, But Multiple Catalysts Are On The Way
seekingalpha.com - May 14 at 8:00 PM |
 | Minerva Neurosciences Inc.
www.barrons.com - May 13 at 7:55 PM |
| Minerva down 11% premarket on "successful" study of seltorexant in MDD
seekingalpha.com - May 13 at 7:55 PM |
 | Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug
finance.yahoo.com - May 13 at 7:55 PM |
| Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
finance.yahoo.com - May 13 at 8:19 AM |
| Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)
finance.yahoo.com - May 7 at 7:00 PM |
| Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT
finance.yahoo.com - May 7 at 8:25 AM |
| Minerva Neurosciences (NERV) Posts Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 7 at 7:58 AM |
| Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:40 PM |
| Minerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 6 at 7:40 PM |
 | Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
www.globenewswire.com - May 6 at 8:22 AM |
| Minerva Neurosciences (NERV) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 2:50 PM |
 | Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6,
www.nasdaq.com - April 29 at 6:42 PM |
| Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
finance.yahoo.com - April 29 at 6:42 PM |
| A Look At The Competitors To Minerva's Roluperidone
seekingalpha.com - April 17 at 8:19 AM |
| Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
finance.yahoo.com - April 11 at 9:14 AM |
 | Minerva Neurosciences, Inc: Minerva Neurosciences to Host Webcast Event on Schizophrenia
www.finanznachrichten.de - March 18 at 8:01 PM |
| Minerva Neurosciences to Host Webcast Event on Schizophrenia
www.nasdaq.com - March 18 at 8:01 PM |
| Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
www.finanznachrichten.de - March 12 at 10:48 PM |
| Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 12 at 10:48 PM |
| Minerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript
finance.yahoo.com - March 12 at 10:48 PM |
| Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT
finance.yahoo.com - March 12 at 10:48 PM |
| Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
finance.yahoo.com - March 12 at 8:32 AM |
| Minerva Neurosciences: 4Q Earnings Snapshot
finance.yahoo.com - March 12 at 8:32 AM |
| Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019
finance.yahoo.com - March 5 at 8:44 AM |
| How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?
finance.yahoo.com - December 20 at 5:37 PM |
| Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
finance.yahoo.com - November 28 at 8:27 AM |
| Early-stage study shows potential expanded therapeutic window for Minerva's roluperidone
seekingalpha.com - November 19 at 5:22 PM |
| Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
finance.yahoo.com - November 19 at 8:19 AM |
| Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - November 16 at 8:16 AM |
| Minerva to host KOL event November 20
seekingalpha.com - November 15 at 5:26 PM |
| Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
finance.yahoo.com - November 15 at 5:26 PM |
| New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - November 9 at 8:23 AM |
| Minerva Delays Roluperidone Data, But Remains On Track For Transformational 2019
seekingalpha.com - November 8 at 8:21 AM |
| Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
finance.yahoo.com - November 7 at 5:47 PM |
| Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT
finance.yahoo.com - November 6 at 8:17 AM |
| Minerva Neurosciences reports Q3 results
seekingalpha.com - November 5 at 5:23 PM |
| Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 5 at 5:23 PM |
 | BRIEF-Minerva Neurosciences Qtrly Loss Per Share $0.31
www.msn.com - November 5 at 8:34 AM |
| Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
finance.yahoo.com - November 5 at 8:34 AM |
| Minerva Neurosciences: 3Q Earnings Snapshot
finance.yahoo.com - November 5 at 8:34 AM |
| Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
finance.yahoo.com - October 29 at 5:02 PM |
| Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis
www.nasdaq.com - October 16 at 8:24 AM |
| Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - October 16 at 8:24 AM |
| Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying
finance.yahoo.com - October 10 at 5:02 PM |
| The Verdict On Minerva
seekingalpha.com - October 9 at 4:56 PM |
 | A Look At Johnson & Johnson's Late Stage Pharmaceuticals Pipeline
www.forbes.com - September 26 at 5:07 PM |
